16428 Lebrikizumab, a high-affinity interleukin-13 inhibitor, improves clinical manifestations in moderate to severe atopic dermatitis: Time course of response from a randomized, double-blinded, placebo-controlled, dose-ranging, phase 2b study
Autor: | Janice Drew, Amy S. Paller, Eric L. Simpson, Lawrence F. Eichenfield, Emma Guttman-Yassky, Ramanan Gopalan, Andrew Blauvelt, April W. Armstrong |
---|---|
Rok vydání: | 2020 |
Předmět: | |
Zdroj: | Journal of the American Academy of Dermatology. 83:AB63 |
ISSN: | 0190-9622 |
Databáze: | OpenAIRE |
Externí odkaz: |